ImmunoCellular (OTCBB: IMUC) provided an update on the site and patient enrollment for ICT-107, currently in a Phase II trial for Brain Cancer. Recall that this is a dendritic cell based cancer vaccine targeting multiple tumor antigens for the treatment of glioblastoma multiforme (GBM or brain cancer).
- The company initiated the trial in 23 centers to enroll up to 160-200 patients, (100 with the HLA-A1/A2 immunological subtypes). 115 patients are enrolled in the study to date, ahead of schedule.
- Enrollment for the trial is expected to be completed by Q2 of 2012 and an interim analysis is expected when 50% of events (32 deaths) have been observed.
- NeoStem's, Progenitor Cell Therapy (PCT) is working with Immunocellular on the "manufacturing".
Conclusion: We discussed IMUC last week and we believe that this dendritic approach is showing compelling data in this unmet medical need. PCT (NeoStem) eliminates any manufacturing concerns, (PCT did most of the clinical manufacturing for Dendreon's Provenge). IMUC looks like an attractive play, and the company is financed through to proof of concept, given that capital was raised earlier in January 2012.